|
| Webinar: Improving the discovery of novel drugs with artificial intelligence Thursday, February 3, 2022 | 2pm ET / 11am PT This webinar will cover the newest and most innovative AI solutions that have been developed for the life sciences industry. Topics include how AI can be used to improve the ability to predict which compounds are likely to make it to late-stage trials, best practices for choosing and partnering with technology developers to maximize the benefits of AI in drug development, and more. Register now. |
GlaxoSmithKline’s HIV prevention injectable Apretude threatens Gilead with FDA blessing. But will doctors use it? Biden buys up 500M rapid, at-home COVID tests to distribute for free in 2022 Biden announces free home COVID testing, emergency hospital support to head off winter omicron surge Pfizer reports patient death in early-stage Duchenne gene therapy trial, halts enrollment AbbVie, after losing Humira trade secrets case, eyes new strategy in Alvotech fight Drug price reforms, Medicaid coverage gap in balance after Manchin opposition to Build Back Better Act Sanofi gambles $1B upfront on preclinical oncology biotech, bagging Amunix for its pipeline of T-cell engagers BD acquires smartphone-powered COVID test partner Scanwell Health Acadia slims Nuplazid label expansion bid in hopes of clinching Alzheimer's dementia nod without extra studies Lilly's atopic dermatitis med scores another late-stage win in attempt to outdo Dupixent FDA alerts medical device makers to cybersecurity risk in popular Apache Log4j software tool Goldman Sachs forecasts positive outlook for insurers in 2022, buoyed by shift to value-based care Featured Story | By Angus Liu After making history with the first complete long-acting regimen for the treatment of HIV, GlaxoSmithKline’s ViiV Healthcare has now made a component of that therapy into a preventative option, threatening a major franchise at Gilead Sciences. read more |
| |
|---|
|
Top Stories By Andrea Park Beginning in January, Americans will be able to visit a website where they can have the tests mailed directly to their homes at no charge. read more By Dave Muoio Free at-home tests, new vaccination centers and hospital bed capacity expansions are all at the crux of President Biden's omicron response. read more By Annalee Armstrong Pfizer reported the death of a young male patient who was participating in an an early-stage trial for the Big Pharma’s Duchenne muscular dystrophy gene therapy. The company paused screening and dosing in the study while it works with the trial site investigator to figure out what happened. read more By Fraiser Kansteiner In a recent complaint filed at the U.S. International Trade Commission (ITC), AbbVie said Alvotech "misappropriated" trade secrets linked to the production of its Humira copycat. As a result, the ITC should bar imports or sales of the biosim in the U.S., lawyers for AbbVie argued. read more By Robert King Democrats are debating what healthcare items to drop in a narrower Build Back Better Act after objections from moderate Sen. Joe Manchin. read more By Nick Paul Taylor Sanofi is betting $1 billion on a preclinical pipeline of anti-cancer T-cell engagers. The upfront outlay, plus up to $225 million in milestones, is set to give Sanofi ownership of West Coast immuno-oncology player Amunix Pharmaceuticals. read more By Conor Hale After working this past year to pair up its rapid COVID-19 antigen test with digital smartphone capabilities, BD is making its relationship with Scanwell Health official. The medtech giant acquired Scanwell for an undisclosed amount and announced plans to fold the tech developer into its integrated diagnostic solutions business. read more By Fraiser Kansteiner After suffering a surprise rejection from the FDA in April, Acadia Pharmaceuticals is making another bid to expand the scope of its Parkinson’s disease med Nuplazid—and it hopes to do so without running additional trials. read more By Annalee Armstrong Watch out, Sanofi and Regeneron. Eli Lilly’s Dupixent rival has posted another round of data showing improvement in atopic dermatitis when combined with topical corticosteroids in a phase 3 trial. read more By Andrea Park A hacking risk discovered last month within the widely used Apache Log4j logging tool has been labeled “the single biggest, most critical vulnerability of the last decade” by the CEO of cybersecurity firm Tenable—and medtech developers aren’t immune. read more By Heather Landi Global investment bank Goldman Sachs projects that the pursuit of value-based care could potentially bring significant payoff for big insurers in 2022. For the next two years, analysts Nathan Rich and Lindsay Golub estimate a potential 13% annual earnings per share growth for large-cap managed care organizations, more than double the firm’s 6% projection for S&P EPS growth, according to a recent report. read more |
| Webinar: A Collaborative Approach to Complex Chemistry Wednesday, January 12, 2022 | 11am ET / 8am PT Complex therapeutics demand complex chemistry expertise. Discover how the right partner can help you overcome complex chemistry challenges through extensive experience, specialised technologies, and true scientific collaboration. Register now. |
|
